Skip to content
Calculator

Athletes · 2027 List

The 2027 Prohibited List: what changed for peptides

WADA publishes a new Prohibited List every year, and the 2027 List takes effect on January 1, 2027. For peptides the headline change is one of wording with real weight: the catch-all section S0 now names peptides among its examples. This page sets out that change, the compounds whose status moved, and what WADA is monitoring.

Last updated November 3, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Every claim sourced · No products sold, no seller named

📋 Key takeaways

Dates: the 2026 List applies to samples until December 31, 2026; the 2027 List from January 1, 2027.13

S0 now names peptides. WADA's note says many unapproved peptides fall under S0 or other classes, and that a peptide not named on the List may still be prohibited and may be harmful to health.2

Monitoring is not a ban. The 2027 Monitoring Program covers the approved GLP-1 drugs semaglutide and tirzepatide, among others.4

On this page

  1. Which List applies when
  2. The S0 change
  3. Compounds whose status changed
  4. What WADA is monitoring in 2027
  5. Frequently asked questions
  6. Related on Grey Peptides
  7. Sources

Which List applies when

WADA approved the 2027 List on September 10, 2026, published it on September 21, and it takes effect on January 1, 2027; until then the 2026 List, in force since January 1, 2026, applies.13 What matters for an athlete is the List in force on the date the sample is collected (our reading of how the Lists are dated; our report on the 2027 List has the background).

The S0 change

S0 prohibits pharmacological substances that no other section addresses and that have no current approval by any governmental regulatory health authority for human therapeutic use.1 WADA's explanatory note for 2027 says many peptides not approved for human use fall under S0, or under other classes such as S2 or S4; that even a peptide not specifically named may still be prohibited and may be harmful to health; and that, for clarity, peptides are now named as examples in S0.2

For an athlete this changes the wording more than the reach: unapproved research peptides such as BPC-157 were already caught by S0 (our reading; the WADA hub sets out how each entry is classified).

Compounds whose status changed

We compared every compound in our encyclopedia against both Lists. The list below is generated from those records.

The change that reaches every unapproved peptide: S0's text now lists “peptides” among its examples of non-approved substances.2

Compound by compound, against our records:

  • Dermorphin: “Not on the 2026 List” became “Unsettled (S0 may apply)” for 2027. WADA monitored dermorphin as a non-prohibited substance in 2026 and dropped it from the 2027 Monitoring Program without adding it to the List; on its face S0 would cover it.

The note also records that dermorphin and its analogues were removed from the Monitoring Program because sufficient information had been collected.2 The dermorphin entry explains its record.

What WADA is monitoring in 2027

The Monitoring Program lists substances that are not prohibited but that WADA wants data on, to detect patterns of misuse.4 In our encyclopedia, for 2027:

  • Buserelin: GnRH analogues in female athletes under 18, in and out of competition4
  • Gonadorelin: GnRH analogues in female athletes under 18, in and out of competition4
  • Goserelin: GnRH analogues in female athletes under 18, in and out of competition4
  • Histrelin: GnRH analogues in female athletes under 18, in and out of competition4
  • Leuprolide: GnRH analogues in female athletes under 18, in and out of competition4
  • Nafarelin: GnRH analogues in female athletes under 18, in and out of competition4
  • Semaglutide: GLP-1 receptor agonists: semaglutide and tirzepatide, in and out of competition4
  • Tirzepatide: GLP-1 receptor agonists: semaglutide and tirzepatide, in and out of competition4
  • Triptorelin: GnRH analogues in female athletes under 18, in and out of competition4

The approved GLP-1 drugs are monitored, not prohibited; the grey-market GLP-1s beside them are a different case, shown on the WADA status page.

Frequently asked questions

When does the 2027 Prohibited List take effect?

January 1, 2027. Samples collected before then are judged against the 2026 List.

Does the 2027 List ban BPC-157 by name?

The 2027 List adds peptides to S0's examples. Whether a given compound is named, and where, is in the table on the WADA status page, which is generated from our record of the List.

Athletes, peptides and testing hub WADA status by compound How testing finds peptides Therapeutic use exemptions Contaminated supplements and products WADA Prohibited List hub Do peptides show up on drug tests? Our report on the 2027 List TB-500 is not thymosin beta-4 The grey market

Sources

The Lists and the note are cited with the date we read them; the compound changes are our dataset records.

  1. World Anti-Doping Agency. Prohibited List 2027, in force January 1, 2027; read September 27, 2026. Each compound's status is our record of that List, kept in the dataset. WADA · Dataset
  2. World Anti-Doping Agency. Prohibited List 2027: Summary of Major Modifications and Explanatory Notes; read September 27, 2026. WADA
  3. World Anti-Doping Agency. Prohibited List 2026, in force January 1, 2026; read September 27, 2026. Each compound's status is our record of that List, kept in the dataset. WADA · Dataset
  4. World Anti-Doping Agency. 2027 Monitoring Program; read September 27, 2026. WADA

This section reports the WADA Prohibited List, the anti-doping standards and published research, and our reading of them. It is not legal advice or an anti-doping ruling: an athlete's own anti-doping organisation gives the answer that counts. Grey Peptides sells nothing, links to no seller and rates none.